Most Popular - A recently announced collaboration with Array BioPharma (ARRY) on a small molecule HER2 inhibitor may be the best thing to happen to Oncothyreon (ONTY) since … Continue Reading
Read NowLong Ideas - It’s been just under five weeks since the PropThink team laid out the investment thesis for Diadexus (DDXS). We said, “We calculate a probability weighted … Continue Reading
Read NowLong Ideas - PropThink Subscribers who followed us into Tekmira (TKMR) at $4.70 in mid-April saw the stock touch a recent high of just over $6.00 early last … Continue Reading
Read NowLong Ideas - Since we initiated coverage of Cubist Pharmaceuticals (CBST) in mid-May, shares of the antibiotics manufacturer are up over 26%, as the company secured a key … Continue Reading
Read NowMost Popular - ImmunoCellular Therapeutics’ (IMUC) on Wednesday the 7th said that the company expects trial results in the fourth quarter of 2013 or first quarter of 2014 … Continue Reading
Read NowMost Popular - Sunshine Heart (SSH), in its first ever quarterly conference call on Wednesday, provided more anecdotal evidence that its C-Pulse device is benefitting late-stage heart failure … Continue Reading
Read NowLong Ideas - Regeneron Pharmaceuticals (REGN), due in large part to the continued growth of Eylea, has become the world’s 5th largest biotechnology company by market capitalization. Regeneron, … Continue Reading
Read Now